Roxithromycin | CAS#80214-83-1 | macrolide antibiotic

MedKoo Cat#: 461436 | Name: Roxithromycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections.

Chemical Structure

Roxithromycin

CAS#80214-83-1

Theoretical Analysis

MedKoo Cat#: 461436

Name: Roxithromycin

CAS#: 80214-83-1

Chemical Formula: C41H76N2O15

Exact Mass: 836.5246

Molecular Weight: 837.05

Elemental Analysis: C, 58.83; H, 9.15; N, 3.35; O, 28.67

Price and Availability

Size	Price	Availability
250mg	USD 150.00	Ready to ship
500mg	USD 250.00	Ready to ship
1g	USD 350.00	Ready to ship
2g	USD 550.00	Ready to ship
10g	USD 750.00	Ready to ship
25g	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Roxithromycin; Roxithromycinum; RU 28965; RU-28965; RU28965; RU 965; RU-965; RU965; Rulide;

IUPAC/Chemical Name

(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-10-(((2-methoxyethoxy)methoxy)imino)-3,5,7,9,11,13-hexamethyloxacyclotetradecan-2-one

InChi Key

RXZBMPWDPOLZGW-XMRMVWPWSA-N

InChi Code

InChI=1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1

SMILES Code

CC[C@H]1OC([C@@H]([C@H]([C@@H]([C@H]([C@](O)(C[C@H](/C([C@@H]([C@H]([C@@]1(O)C)O)C)=N\OCOCCOC)C)C)O[C@@H]2O[C@@H](C[C@H](N(C)C)[C@H]2O)C)C)O[C@H]3C[C@@](OC)([C@H]([C@@H](O3)C)O)C)C)=O

Appearance

Solid powder

Purity

95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Certificate of Analysis

View CoA: current batch, Lot#A24M09B25

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 837.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shafuddin E, Mills GD, Holmes MD, Poole PJ, Mullins PR, Black PN. A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. J Negat Results Biomed. 2015 Sep 7;14:15. doi: 10.1186/s12952-015-0034-8. PubMed PMID: 26346300; PubMed Central PMCID: PMC4562194. 2: Choi Y, Koh SJ, Lee HS, Kim JW, Gwan Kim B, Lee KL, Kim JS. Roxithromycin inhibits nuclear factor kappaB signaling and endoplasmic reticulum stress in intestinal epithelial cells and ameliorates experimental colitis in mice. Exp Biol Med (Maywood). 2015 Dec;240(12):1664-71. doi: 10.1177/1535370215591829. Epub 2015 Jun 18. PubMed PMID: 26088864; PubMed Central PMCID: PMC4935332. 3: Dai YR, Wu HY, Wu LQ, Xu H, Yin J, Yan SS, Zeng WX. Roxithromycin reduces the viability of cultured airway smooth muscle cells from a rat model of asthma. Eur Rev Med Pharmacol Sci. 2014;18(23):3564-72. PubMed PMID: 25535124. 4: Choe HS, Lee SJ, Han CH, Shim BS, Cho YH. Clinical efficacy of roxithromycin in men with chronic prostatitis/chronic pelvic pain syndrome in comparison with ciprofloxacin and aceclofenac: a prospective, randomized, multicenter pilot trial. J Infect Chemother. 2014 Jan;20(1):20-5. doi: 10.1016/j.jiac.2013.07.010. Epub 2013 Dec 11. PubMed PMID: 24462419. 5: Britzi M, Berkovitch M, Soback S, Leibovitz A, Segal R, Smagarinsky M, Lubart E. Roxithromycin Pharmacokinetics in Hospitalized Geriatric Patients: Oral Administration of Whole Versus Crushed Tablets. Ther Drug Monit. 2015 Aug;37(4):512-5. doi: 10.1097/FTD.0000000000000203. PubMed PMID: 26186658. 6: Agbokponto JE, Luo Z, Liu R, Liu Z, Liang M, Ding L. Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. Eur J Pharm Sci. 2015 Mar 10;69:37-43. doi: 10.1016/j.ejps.2014.12.019. Epub 2015 Jan 2. PubMed PMID: 25559065. 7: Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ. 2014 Aug 19;349:g4930. doi: 10.1136/bmj.g4930. PubMed PMID: 25139799; PubMed Central PMCID: PMC4138354. 8: Wosicka-Frąckowiak H, Cal K, Stefanowska J, Główka E, Nowacka M, Struck-Lewicka W, Govedarica B, Pasikowska M, Dębowska R, Jesionowski T, Srčič S, Markuszewski MJ. Roxithromycin-loaded lipid nanoparticles for follicular targeting. Int J Pharm. 2015 Nov 30;495(2):807-15. doi: 10.1016/j.ijpharm.2015.09.068. Epub 2015 Oct 9. PubMed PMID: 26456292. 9: Suke SG, Chahande AD, Kasliwal RH, Asnani AJ. Roxithromycin potency quantification in pharmaceutical preparation by applying a validated bioassay method and comparison with HPLC analysis. Ann Pharm Fr. 2015 Sep;73(5):340-50. doi: 10.1016/j.pharma.2015.04.007. Epub 2015 May 26. PubMed PMID: 26021576. 10: Morimura S, Sugaya M, Kai H, Miyagaki T, Asano Y, Tada Y, Kadono T, Murakami T, Sato S. Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation. J Dermatol. 2014 Jan;41(1):57-62. doi: 10.1111/1346-8138.12351. PubMed PMID: 24438145. 11: Wu LQ, Wang RL, Dai YR, Li FQ, Wu HY, Yan SS, Wang LR, Jin LD, Xia XD. Roxithromycin suppresses airway remodeling and modulates the expression of caveolin-1 and phospho-p42/p44MAPK in asthmatic rats. Int Immunopharmacol. 2015 Feb;24(2):247-255. doi: 10.1016/j.intimp.2014.11.015. Epub 2014 Nov 25. PubMed PMID: 25479721. 12: Lee JH, Park YJ, Oh JH, Lee YJ. Decrease in gastrointestinal absorption of roxithromycin in bile duct cannulated rats due to depletion of bile salts. Biopharm Drug Dispos. 2013 Sep;34(6):360-4. doi: 10.1002/bdd.1845. Epub 2013 May 23. PubMed PMID: 23703541. 13: Takakusagi K, Takakusagi Y, Suzuki T, Toizaki A, Suzuki A, Kawakatsu Y, Watanabe M, Saito Y, Fukuda R, Nakazaki A, Kobayashi S, Sakaguchi K, Sugawara F. Multimodal biopanning of T7 phage-displayed peptides reveals angiomotin as a potential receptor of the anti-angiogenic macrolide Roxithromycin. Eur J Med Chem. 2015 Jan 27;90:809-21. doi: 10.1016/j.ejmech.2014.12.015. Epub 2014 Dec 12. PubMed PMID: 25528335. 14: Skovbølling SL, Lindelof M. [Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin]. Ugeskr Laeger. 2014 Oct 6;176(41). pii: V04140212. Danish. PubMed PMID: 25331664. 15: Rocas P, Hoyos-Nogués M, Rocas J, Manero JM, Gil J, Albericio F, Mas-Moruno C. Installing multifunctionality on titanium with RGD-decorated polyurethane-polyurea roxithromycin loaded nanoparticles: toward new osseointegrative therapies. Adv Healthc Mater. 2015 Sep 16;4(13):1956-60. doi: 10.1002/adhm.201500245. Epub 2015 Aug 14. PubMed PMID: 26274361. 16: Liu J, Lu G, Wang Y, Yan Z, Yang X, Ding J, Jiang Z. Bioconcentration, metabolism, and biomarker responses in freshwater fish Carassius auratus exposed to roxithromycin. Chemosphere. 2014 Mar;99:102-8. doi: 10.1016/j.chemosphere.2013.10.036. Epub 2013 Nov 8. PubMed PMID: 24210552. 17: Wahba ME. Liquid chromatographic determination of roxithromycin: application to stability studies. J Chromatogr Sci. 2013 Jan;51(1):44-52. doi: 10.1093/chromsci/bms104. Epub 2012 Jun 19. PubMed PMID: 22718747. 18: Das S, Mondal S, Dey JK. Roxithromycin-induced toxic epidermal necrolysis. Ther Drug Monit. 2012 Aug;34(4):359-62. doi: 10.1097/FTD.0b013e318260b087. PubMed PMID: 22777150. 19: Aucamp M, Stieger N, Barnard N, Liebenberg W. Solution-mediated phase transformation of different roxithromycin solid-state forms: Implications on dissolution and solubility. Int J Pharm. 2013 Jun 5;449(1-2):18-27. doi: 10.1016/j.ijpharm.2013.03.048. Epub 2013 Apr 8. PubMed PMID: 23578825. 20: Ding J, Zhang F, Zhang X, Wang L, Wang C, Zhao Q, Xu Y, Ding L, Ren N. Determination of roxithromycin from human plasma samples based on magnetic surface molecularly imprinted polymers followed by liquid chromatography-tandem mass spectromer. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:221-228. doi: 10.1016/j.jchromb.2015.08.001. Epub 2015 Aug 4. PubMed PMID: 26300321.